EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti‐PD‐1 immunotherapy efficacy in colorectal cancer liver metastasis

Yizhi Zhan iD, Jinsong Xu, Zhanqiao Zhang, Yating Hu, Yongsheng Li, Junying Qian, Yunyan Ling, Dehua Wu, Haijun Deng, Guoxin Li, Zhiyong Shen, Yuan Fang

Cancer Communications · 2025-10 · 45 (10) · 1203-1228

DOI: 10.1002/cac2.70047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 16.07.2025. Verfasst von Yizhi Zhan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Colorectal Neoplasms, Phosphotransferases (Alcohol Group Acceptor), Liver Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, the Guangdong Basic and Applied Basic Research Foundation, Science and Technology Program of Guangzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal cancer liver metastasis (CRLM) is characterized by an immunosuppressive microenvironment and a blunted response to immunotherapy. Notably, tumor‐associated macrophages (TAMs) play a critical role in modulating immune responses and exhibit significant heterogeneity in CRLM. Sphingosine kinase 1 (SPHK1) serves as a pivotal kinase in maintaining the balance between ceramide and sphingosine‐1‐phosphate (S1P) levels. However, the effects of SPHK1 within TAMs on tumor immune evasion during CRLM remain elusive. This study aimed at investigating the role of TAM‐intrinsic SPHK1 in tumor immunosuppressive microenvironment in CRLM.

Methods

SPHK1 expression levels in TAMs were estimated by immunofluorescence and bioinformatics analysis. Several animal models were established to elucidate the role of SPHK1 in tumor immunity reprogramming in vivo. Flow cytometry, cytokine assay, and transwell assay were conducted to investigate the effects of SPHK1 in TAMs in cell‐cell communication in vitro. RNA‐sequencing, Western blotting, and quantitative real‐time polymerase chain reaction were used to explore the molecular mechanism by which SPHK1 activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in TAMs.

Results

We found that SPHK1 was mainly expressed in TAMs and identified SPHK1 + TAMs as associated with CRLM and diminished efficacy of immunotherapy in human patients. These SPHK1 + TAMs exhibited strong immunosuppressive activities by inducing CD8 + T cell exhaustion with high programmed cell death 1 (PD‐1) expression via the interaction between TAMs and CRC cells. Mechanistically, SPHK1‐produced S1P exerted an autocrine effect to activate NLRP3 inflammasome and interleukin 1 beta (IL‐1β) release via nuclear factor‐kappa B (NF‐κB) and hypoxia inducible factor 1 subunit alpha (HIF‐1α) signaling in TAMs. Paracrine IL‐1β then upregulated the expression of monocyte chemoattractants and ADAM metallopeptidase domain 17 (ADAM17) sheddase in CRC cells, resulting in TAM infiltration and CD8 + T cell dysfunction in the liver microenvironment. Furthermore, combining SPHK1‐targeting treatments with anti‐PD‐1 therapy or radioimmunotherapy largely stalled liver metastasis and caused a significant extension of lifespan in preclinical mouse models.

Conclusions

Our findings highlighted the role of SPHK1 of TAMs in facilitating CRLM by promoting CD8 + T cell dysfunction and immunosuppressive microenvironment. Combining SPHK1 blockade with anti‐PD‐1 therapy may be a promising treatment regimen for patients with CRLM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentColorectal NeoplasmsPhosphotransferases (Alcohol Group Acceptor)Liver NeoplasmsTumor-Associated MacrophagesProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAnimalsHumansMiceCell Line, TumorImmunotherapyFemaleMaleSphingosine Kinase

Stichwörter der Autor:innen

CD8+ T cellsSPHK1colorectal cancer liver metastasisimmunotherapytumor‐associated macrophages

Substanzen

Phosphotransferases (Alcohol Group Acceptor)Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsSphingosine KinasePDCD1 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
  • Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, P. R. China.
  • Guangdong Province Key Laboratory of Molecular Tumor Pathology, Guangzhou, Guangdong, P. R. China.
  • Department of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
  • Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.

ORCID-Profile: Yizhi Zhan

Förderung

  • National Natural Science Foundation of China
  • the Guangdong Basic and Applied Basic Research Foundation
  • Science and Technology Program of Guangzhou
  • Outstanding Youth Cultivation Program of Nanfang Hospital of Southern Medical University
  • China Postdoctoral Science Foundation

Zitieren

APA

Zhan, Y., Xu, J., Zhang, Z., Hu, Y., Li, Y., Qian, J., Ling, Y., Wu, D., Deng, H., Li, G., Shen, Z., & Fang, Y. (2025). Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti‐PD‐1 immunotherapy efficacy in colorectal cancer liver metastasis. Cancer Communications, 45(10), 1203-1228. https://doi.org/10.1002/cac2.70047

Vancouver

Zhan Y, Xu J, Zhang Z, Hu Y, Li Y, Qian J, et al. Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti‐PD‐1 immunotherapy efficacy in colorectal cancer liver metastasis. Cancer Communications. 2025;45(10):1203-1228. doi:10.1002/cac2.70047

BibTeX
@article{Zhan2025,
  author = {Zhan, Yizhi and Xu, Jinsong and Zhang, Zhanqiao and Hu, Yating and Li, Yongsheng and Qian, Junying and Ling, Yunyan and Wu, Dehua and Deng, Haijun and Li, Guoxin and Shen, Zhiyong and Fang, Yuan},
  title = {Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti‐PD‐1 immunotherapy efficacy in colorectal cancer liver metastasis},
  journal = {Cancer Communications},
  year = {2025},
  volume = {45},
  number = {10},
  pages = {1203--1228},
  doi = {10.1002/cac2.70047}
}
Kostenlos starten →